Novartis (NVS) said Friday the US Food and Drug Administration has approved its radioligand therapy Pluvicto for earlier use before chemotherapy in prostate cancer patients.
The new indication allows the use in patients with metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor therapy and are considered appropriate to delay chemotherapy, Novartis said.
The approval triples the number of patient population eligible to receive Pluvicto, the company said.
Price: 112.29, Change: +0.89, Percent Change: +0.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.